The present invention provides an erythropoietin-derived peptide having an amino acid sequence as shown in SEQ ID NO: 1. The present invention also provides a method for preparing the above-described erythropoietin-derived peptide. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating nerve cell damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating hypoxic brain damage. Also provided is the use of the above-described erythropoietin-derived peptide for the preparation of a medicament for treating epilepsy. The novel EPO-derived peptide of the present invention has a small molecular weight and can penetrate the blood-brain barrier. Moreover, it is a small-molecule polypeptide derived from a functional protein in the human body, having an extremely small side effect to the human body compared with other developed and synthesized drugs, thereby it has a good clinical application prospect. If the present invention is applicable to clinical practice, it will become a novel neuroprotective drug for preventing and treating central nervous system diseases, providing a new therapeutic direction for patients with nerve damage.
